Coach — Immune Function
Immunity is usually described as two armies, innate and adaptive, and then treated with ways to turn the volume up or down. The working hypothesis here starts one layer upstream. It asks which cells are conducting and which are executing, and whether the energy supply that powers both can still bring a fight to a clean end.
Safety before ideas
This essay does not replace immunology, rheumatology, infectious-disease, allergy, or cancer care. The extended report begins with its cautions: "Do not stop or start immune-modulating drugs, biologics, steroids, vaccines, antimicrobials, epinephrine readiness, or allergen-avoidance plans from this page. LMR and other CBC ratios are imperfect dashboards — not diagnoses — and require qualified clinical correlation."
Several practical cautions follow. A single low ratio on a blood count, a cytokine panel, a Lyme test, or an alpha-gal antibody level is not an understanding of a case, and none of them is a reason to overlook infection, cancer, anaphylaxis risk, drug toxicity, or an acute rheumatologic emergency. DMARDs and checkpoint inhibitors are not stopped, and vaccine schedules are not changed, because an essay reframed the biology. Unsupervised prolonged fasting, extreme elimination diets, "immune detox" programs, home courses of methylene blue as an antimicrobial, and piles of supplements are not immunology. No peptide, hormone, or GLP-1 "immune recovery" protocol is offered here. Nothing promises a cure, freedom from medication, or that ketosis alone cures Lyme disease. If the question is whether to pause a biologic or an antibiotic course for a metabolic plan, that decision belongs with the physician who knows the case.
One more point belongs here. Immune illness, including autoimmunity, chronic infection, and leprosy, is never a sin or a moral failure. It is biology, and the people who live with it deserve care, not judgment.
Conductors and soldiers
The innate and adaptive taxonomy has real value for evolution, vaccines, and some immune deficiencies. But living cells constantly cross those lines, and some innate cells show a kind of memory. The report proposes a more functional division. Orchestrators, the conductors, process information and send directional signals, including the signals that end a response; helper and regulatory T cells are the main examples, with dendritic cells and early natural killer and innate lymphoid cells bridging. Effectors, the soldiers, carry out the work: monocytes and macrophages, neutrophils, cytotoxic T cells, and antibody-making plasma cells.
Evolution built these layers in order. The oldest pairing, natural-killer-like coordinators with phagocytes, solved defense cheaply. About 500 million years ago, jawed vertebrates added antigen-specific memory cells, which brought precision and memory at a high energy price. In the report's account, when the body runs short of energy for long periods, the cheap system cannot finish the job and the expensive memory layer becomes noisy. Autoimmunity and chronic inflammation then look like failed coordination on a strained metabolic base, rather than a lymphocyte disease in isolation.
A cheap reading from a routine blood count
The lymphocyte-to-monocyte ratio, or LMR, comes from an ordinary complete blood count. The report treats it as a practical but imperfect reading of the balance between conductors and soldiers. Research cohorts commonly discuss values above about 4 to 5 as lymphocyte-dominant and values below about 3 to 4 as monocyte-dominant, although individual baselines and trends matter more than any universal cutoff. Lower values have been linked in studies to worse outcomes after acute coronary syndromes, in several cancers, after strokes from narrowed brain arteries, and in severe infections. Metabolic syndrome, obesity, and insulin resistance tend to lower the ratio, and so do stress hormones, aging, and glucocorticoid medicines.
The report is careful about what the number can do. It is "a dashboard, not a diagnosis," confounded by drugs, acute illness, and lab timing. If a physician follows it, the useful way is as a trend: the same lab, morning draws, and readings taken away from acute illness or steroid courses. It is not something to treat on its own. The other immune readings stay with the treating team, such as CRP trajectories, disease-specific antibodies, and activity scores.
Inflammation that never stood down
The report's companion essay on inflammation makes the central claim. Inflammation mobilizes resources: it redirects glucose, changes fat handling, and increases blood flow, and activated immune cells switch to fast, glycolytic metabolism. In acute infection or injury that is adaptive. Once the need passes and cells recover their energy, resolution programs take over, and those programs are themselves energy-intensive. The hypothesis is that "much persistent inflammation functions as a compensatory response to chronic cellular bioenergetic insufficiency rooted in mitochondrial energy-production failure." When the deficit continues, the call for help never stops.
Several modern conditions keep the deficit going, in this view: seed oils that damage mitochondrial membranes, large loads of refined carbohydrate without matching demand, disrupted circadian rhythms, unrelieved stress, and micronutrient gaps. Regulatory T cells, which rely on oxidative metabolism, lose ground to effector cells. The report also states its caveats plainly. "Not all inflammation is compensatory; primary infection-driven defense and genetically driven autoimmunity remain real. Causality is often bidirectional." It does not claim every inflammatory state reduces to energy failure, only that a substantial and under-appreciated share of persistent inflammation arises against a background of chronic cellular energy deficit. The deeper treatment is in the report's section on inflammation as compensation.
Ticks, Lyme disease, and alpha-gal
Lyme disease and alpha-gal syndrome are usually handled as separate problems: an infection treated with antibiotics, and a delayed allergy to a sugar found in mammalian meat, managed by strict avoidance. The report reads both as tick-borne energy loads. Mounting an immune response is among the most energy-intensive things a mammal does. In someone whose mitochondrial reserve is already thin, the demand can exceed capacity, cells shift toward glycolysis, and recovery stalls. Studies of persistent symptoms after Lyme treatment show changes in fat, bile-acid, and acylcarnitine metabolism, and increased mitochondrial superoxide in blood cells. Alpha-gal adds a twist: avoiding red meat is necessary for safety, but it removes a concentrated supply of carnitine, CoQ10, heme iron, B vitamins, and protein just when repair demand is high, so nutrient gaps deserve attention.
The report is firm about what this does not mean. It is "not a claim that chronic symptoms are “all mitochondrial,” not a license to skip antibiotics or avoidance, and not a dosing protocol for methylene blue, NAD+ precursors, or any antimicrobial." Timely antibiotics, epinephrine readiness, and avoidance of hidden mammalian ingredients and cross-reactive medicines keep their full value. The report says it "invents no doses, stacks, or DIY antimicrobial courses." Its fuller account is in the section on Lyme and alpha-gal.
The supportive pillars are the familiar ones. Fuel means fewer industrial seed oils, nutrient-dense animal proteins and fats where appropriate (or physician-supervised alpha-gal-safe alternatives such as fish, shellfish, tolerated poultry, and eggs), fermented foods and resistant starches for the gut, and ketosis or time-restricted eating only where clinically appropriate. Circadian care means morning light, consistent sleep, dim evenings, and steady meal times; the report calls sleep disruption in Lyme and alpha-gal a recovery bottleneck. Strength means progressive resistance and steady aerobic work, with careful respect for post-exertional malaise, the crash that can follow overexertion. More on food is in the fuel essay, and the nerve-to-immune signaling link is described in the signals essay.
Leprosy
Leprosy has its home in immunology and also appears in the dermatology essay. The report describes Mycobacterium leprae as "an extreme specialist in dissociation." With a drastically reduced genome, it depends wholly on its host and dismantles the host cell's mitochondria. Membrane potential collapses, oxidative phosphorylation declines, and the reactive oxygen signals that normally trigger defense are suppressed. Infected cells fill with lipid, and the bacterium uses scavenged cholesterol to build its own protective lipids, creating a quiet, immune-tolerant niche. Schwann cells lose the ability to support nerves, and sensation, especially pain, disappears. Leprosy is an infection with effective treatment, not a curse and not a judgment. As the report puts it, "Any question about diagnosis or treatment belongs with your own physician." The full essay is the metabolic hypothesis of leprosy.
Order of questions
The sequence is plain. First come acute and specialty problems: sepsis, organ-threatening autoimmune disease, anaphylaxis risk, infection on immune-suppressing drugs, cancer emergencies, and early disseminated Lyme disease that needs antibiotics. Then the everyday ground of food, light, sleep, and training, coordinated with the treating team and kept alpha-gal-safe when required. Then capacity is tracked beside the blood counts, CRP, antibody tests, and allergy and infection follow-up the physicians already run. The common measures of capacity are gathered in one place, and the blood-count reading above is summarized under what to measure. Steroid tapers, biologic starts and stops, antimicrobial courses, vaccine timing, epinephrine readiness, and alpha-gal avoidance stay with the licensed team.
When immune drugs, antibiotics, or strict avoidance bring real control, that deserves celebrating. It is also worth continuing to watch infection risk, lean mass, sleep, nutrient gaps, and metabolic flexibility, because a quiet cytokine panel or a negative test is not the same as repaired mitochondria. Two opposite errors are worth naming. One chases CRP while sleep and strength collapse. The other rejects indicated immunosuppression, antimicrobials, or allergen avoidance out of ideology, or tries extreme diets or prolonged fasting while on steroids or biologics. A third is quieter: avoiding mammalian products without watching what that removes from the diet.
Limits and related topics
This is a working hypothesis. The report states that it is "Not a randomized-trial verdict that mitochondrial-first strategies outperform guideline immunology/rheumatology/ID/allergy care as monotherapy." It "Does not deny the clinical necessity of antimicrobials, vaccines, biologics, steroids, epinephrine readiness, allergen avoidance, or checkpoint therapy when indicated; does not authorize stopping them from a webpage." It also names what would weaken it: if capacity-restoring care in post-Lyme illness and alpha-gal produced no measurable gains in mitochondrial markers and symptoms while antibiotics and avoidance were controlled for, the claim would lose ground.
Several topics continue from here. Autoimmune gastritis is treated in the GI report, with its counseling tone in the GI essay. Some "autoimmune" skin rashes are discussed in the dermatology report, and immune evasion in tumors in the cancer report. The gut and mouth as one partnership with the host appear in the report on the holobiont. The brain essay and the GI essay continue the story of microglia and the gut barrier. For the full argument, read the extended report on immune function. The short version is in the lessons. Talk with your own physician before changing medications or supplements.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
See the notice at the top of this page. Working hypothesis, not medical advice. Individual care requires personalized evaluation by a qualified physician.